Read more

March 24, 2021
1 min read
Save

Top in endocrinology: Vitamin D and COVID-19, ADHD and autism risk in type 1 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new study reinforces previous reports that lower vitamin D levels are associated with an increased risk for developing COVID-19, especially among Black adults. It was the top story in endocrinology last week.

Another top story was about an association between high HbA1c in children with type 1 diabetes and an increased risk for neurodevelopment disorders, including ADHD and autism spectrum disorders.

Vitamin D Pills
Source: Adobe Stock

Read these and more top stories in endocrinology below:

Vitamin D level associated with COVID-19 risk for Black adults

Black adults with an adequate vitamin D level were still significantly more likely to test positive for COVID-19 compared with Black adults with a vitamin D level of at least 40 ng/mL, data from a single-center study show. Read more.

High HbA1c in type 1 diabetes linked to increased risk for neurodevelopment disorders

Children with type 1 diabetes have an increased risk for developing neurodevelopment disorders, with the risk greater for those with a high HbA1c, according to a study published in Diabetologia. Read more.

CV benefits of type 2 diabetes agents may extend to type 1, but more data needed

Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD, but more robust data are needed for the type 1 population. Read more.

Insulinemic and inflammatory diets increase type 2 diabetes risk for postmenopausal women

Postmenopausal women consuming a high proinflammatory or hyperinsulinemic diet have an increased risk for developing type 2 diabetes, according to data from the Women’s Health Initiative published in Diabetes Care. Read more.

Zoledronic acid maintains BMD gains after teriparatide, denosumab combination therapy

Following short-term therapy with teriparatide plus denosumab with a single dose of zoledronic acid may prevent bone loss associated with denosumab cessation among postmenopausal women, according to a study published in the Journal of Bone and Mineral Research. Read more.